China Announces New Initiatives to Level the Playing Field for Innovative and Generic Drugs

Published date17 April 2018
Law FirmRopes & Gray LLP
AuthorKatherine Wang
Subject MatterDrug Testing,Patents,China,Manufacturers,Hospitals,Tax Incentives,SIPO,Innovation,Imports,Medical Reimbursement,Physicians,Prescription Drugs,Risk Mitigation,Generic Drugs,Compulsory Licenses,Incentives,Multinationals,Patent Infringement,CFDA,Research and Development,Health Care Providers,Intellectual Property Protection,Pharmaceutical Industry

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT